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Abstract
Background—Antidepressants may increase the risk of fractures by disrupting sensory-motor 
function, thereby increasing the risk of falls, and by decreasing bone mineral density and 
consequently increasing the fall- or impact-related risk of fracture. Selective serotonin reuptake 
inhibitor (SSRI) antidepressants appear to increase fracture risk relative to no treatment, while less 
is known about the effect of serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants, 
despite SNRIs being prescribed with increasing frequency. No prior study has directly examined 
how fracture risk differs among patients initiating SNRIs versus those initiating SSRIs.
Objective—The objective of this study was to assess the effect of SNRI vs. SSRI initiation on 
fracture rates.
Data source—Data came from a PharMetrics claims database, 1998–2010, which is comprised 
of commercial health plan information obtained from managed care plans throughout the US.
Methods—We constructed a cohort of patients aged 50 years or older initiating either of the two 
drug classes (SSRI, N=335,146; SNRI, N=61,612). Standardized mortality weighting and Cox 
proportional hazards regression were used to estimate hazard ratios for fractures by antidepressant 
class.
Results—In weighted analyses, the fracture rates were approximately equal in SNRI and SSRI 
initiators: hazard ratios for the first one and five-year periods following initiation were, 
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respectively, 1.11 (95% CI: 0.92–1.36) and 1.06 (95% CI: 0.90–1.26). For the sub-group of 
patients with depression who initiated on either SNRIs or SSRIs, those initiating SNRIs had a 
modestly, but not significantly elevated fracture risk, compared with those who initiated on SSRIs, 
hazard ratio = 1.31 (95% CI: 0.95–1.79).
Conclusions—We found no evidence that initiating SNRIs rather than SSRIs materially 
influenced fracture risk among a cohort of middle-aged and older adults.
1. Introduction
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs) have become the mainstream pharmacological treatments for patients 
with depressive disorders since the late 1990s [1, 2], due in part to the perception that SSRIs 
and SNRIs have more favorable side-effect profiles than do older drugs such as tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) [3–6], with the possible 
exception of fracture risk, which is of particular concern among older adults [7]. 
Antidepressants have been hypothesized to increase fracture risk among older adults through 
three mechanisms: 1) antidepressants can cause dizziness at initiation of the drug, increasing 
the risk of falls and resulting fractures [8, 4]; 2) serotonin-affecting drugs, such as SSRIs, 
down regulate osteoblast activity and thereby, in time, decrease bone mineral density, 
increasing the risk of sustaining a fracture after a fall or other impact [8, 3, 9, 10]; and 3) 
norepinephrine-affecting drugs, such as SNRIs, may play a role in osteoblast activity and 
may result in reduced bone density by increasing bone resorption [11, 12].
Existing literature examining the link between antidepressant use and fractures largely 
focuses on three antidepressants classes: SSRIs, TCAs, and MAOIs [8, 13, 3, 14, 15]. SSRIs 
have been weakly linked with an increased risk of fracture when compared to both TCAs 
and MAOIs [8, 14]. Excess fracture risk has been shown in users of SSRIs and SNRIs when 
compared to non-users [9, 3, 4, 16].
SSRIs’ risk profile has been studied extensively, but SNRIs’ safety concerns are currently 
less well-studied, especially as the drugs relate to risk of fractures and bone fragility [8, 13, 
3, 14, 4]. To our knowledge, the current study is the first to directly compare the risk of 
fractures between SSRIs and SNRIs.
2. Methods
2.1 Data Source and Patients
The PharMetrics Claims Database used in this study was purchased from IMS Health and is 
comprised of commercial health plan information obtained from managed care plans 
throughout the United States. The database includes medical and pharmaceutical claims for 
over 61 million unique patients from over 98 health plans (approximately 16 million covered 
lives per year). The database includes inpatient and outpatient diagnoses (in International 
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] format) and 
procedures (in Current Procedure Terminology [CPT-4] and Health Care Common 
Procedure Coding System [HCPCS] formats) as well as both retail and mail order records of 
all reimbursed dispensed prescriptions. Available data on prescriptions include the National 
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Drug Code (NDC) as well as the quantity, number of days supplied, and the date of 
dispensing. Additional data elements include demographic variables (age, gender, 
geographic region), provider specialty, and start and stop dates of health-plan enrollment. 
Only health plans that submit data for all members are included in the database.
The current cohort study involves commercially-insured US patients 50 years of age or older 
who initiated use of SSRIs or SNRIs between January 1, 1998 and December 31, 2010 (the 
most recent data set available from the PharMetrics Claims Database.) Initiation was defined 
as filling an SSRI or SNRI antidepressant prescription without evidence of having filled a 
prescription for any class of antidepressants in the preceding 12 months. Such initiators are 
referred to throughout as “new users.” Primary analyses focused on the first treatment 
episode initiated during the study period. Subjects were required to be actively enrolled in a 
health plan with prescription benefits that contributed data to our claims database (see 
below) during the 15 months prior to initiation (i.e., 12 months for baseline covariate 
assessment and an additional 3 months to allow uniform assessment of all patients based on 
a 60 day grace period and a usual antidepressant supply of 30 days).
2.2 Medication Exposure
Medications were classified as SSRIs or SNRIs. SSRIs studied were citalopram 
hydrobromide, fluoxetine hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, 
and sertraline hydrochloride; SNRIs studied were venlafaxine hydrochloride and duloxetine 
hydrochloride. Patients initiating more than one antidepressant agent on the same day were 
excluded.
2.3 Follow-up
Exposure status was assigned based on the initiated medication and carried forward. Study 
follow-up began on the day after initiation of the first antidepressant therapy. For each 
patient we created a record of drug coverage by listing consecutive prescription fills, based 
on dispensing dates and reported days supply. When a dispensing occurred before the 
previous prescription should have run out, use of the new prescription is assumed to begin 
the day after the end of the old prescription. Since users of any prescription medicine, 
especially chronic users, may experience relatively brief episodes without a supply of 
medicine or may skip taking the medicine some days, our primary analyses allowed for up 
to 60 extra days to elapse beyond the provided days supply before censoring (i.e., we use a 
60 day grace period, twice the most common days supply). Note, a person contributes 
information, and is thus included in the number of patients contributing to any post-initiation 
interval, if they are eligible to contribute time for the given analysis. Therefore, for the as 
treated analysis, the person must still be on their initial treatment at the start of the time 
period; for the first treatment carried forward analysis, the person must only continue to be 
enrolled in the health care plan at the start of the time period.
Patients were also censored at the date they switched agents (including when switching 
occurred within antidepressant class), added other antidepressant agents to the initiated 
regimen (i.e., treatment augmentation), ended enrollment in their health insurance plan, or 
the end of the study period, whichever came first. Our rationale for censoring was based on 
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the knowledge that because more SSRI drugs exist than do SNRI drugs, switching agents 
even within classes had the potential to introduce differential bias and thus introduce 
asymmetry into our analyses. New users were not allowed to become new users again; 
patients who were prevalent users at the start of their enrollment were allowed to become 
new users later during the study period.
2.4 Outcome
The occurrence of hip, humerus, radius, and ulna fractures during follow-up was our 
outcome of interest. These fractures were defined as a medical claim with an International 
Classification of Diseases, Ninth Revision (ICD-9) external cause of injury code (E-code) of 
hip (733.14 or 820.xx), humerus (733.11 or 812.xx) or radius/ulna (733.12 or 813.xx) 
fracture diagnosis.
2.5 Patient Characteristics
Patient characteristics considered as potential confounders were age, sex, and several 
indicators of past year medical comorbidity based on inpatient, outpatient, and pharmacy 
claims, including the number of acute hospitalizations for non-psychiatric reasons, number 
of outpatient visits, constituents of the Charlson Comorbidity Index score, and number of 
distinct generic drugs filled. Psychiatric risk factors studied were the number of acute 
psychiatric hospitalizations, the number of acute hospitalizations for substance abuse, 
psychiatric comorbidity, and suicide ideation/attempts. Drug initiators were also sub-
categorized as having or not having a depression diagnosis in order to parse out any 
potential effect modification on fracture risk. For drug initiators with a depression diagnosis, 
a hierarchy of depression severity was constructed for each patient as a function of the 
proximity of the most recent depression diagnosis to antidepressant initiation (i.e., within 30 
days of antidepressant initiation vs. within 31–360 days of initiation) and whether the 
diagnosis was an inpatient or outpatient diagnosis. For inpatient diagnoses, depression 
diagnosis was further characterized as to whether the diagnosis was the primary or 
secondary diagnosis of record. For outpatient diagnoses, persons with a single depression 
diagnosis were distinguished from those with multiple depression diagnoses in the year prior 
to initiation of antidepressant therapy. Other psychiatric disorders were defined as the 
presence of at least one inpatient or outpatient diagnostic code. The disorders studied were 
anxiety or sleep disorders, substance abuse, attention deficit hyperactivity disorder, 
cognitive impairment or dementia, bipolar disorder, schizophrenic disorder, and personality 
disorders. In addition to psychiatric comorbidities, we measured a number of general 
medical comorbidities, including malignant neoplasms, opiate use, stroke and transient 
ischemic attack, and Parkinson disease, all of which are listed in Table 1. Risk factors for the 
outcome of interest were diagnostic codes for fractures or medical procedures performed on 
the hip, humerus, and/or radius/ulna.
2.6 Statistical Analyses
We estimated the propensity for initiating SNRIs versus SSRIs using multivariable logistic 
regression including all of the covariates outlined above. Standardized mortality weighting 
[17] was applied to weight the SNRI cohort by the propensity score odds to achieve a 
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similar distribution of patient characteristics in SNRI initiators as in SSRI initiators. We 
chose to weight SNRI patients to SSRI patients because, by current prescribing patterns, 
individuals are most commonly prescribed SSRIs as first-line antidepressant medications. 
Thus, our study examines what the fracture risk differential would be among patients who 
started on SNRIs (the less common practice) as opposed to SSRIs, and if this would be 
beneficial in terms of alleviating fracture risk. Fracture rates were calculated for patients 
exposed to SNRI vs. SSRI over the entire exposure period using weighted Poisson 
regression. Robust methods were used to calculate 95% confidence intervals. We also used 
weighted Cox proportional hazard models to estimate hazard ratios of medication class on 
fracture stratified by 1 and 5-year time periods.
3. Results
3. 1 Description of cohort
Between January 1, 1998 and December 31, 2010, 335,146 patients initiated SSRI 
antidepressants and 61,612 patients initiated SNRI antidepressants. As shown in Table 1, 
baseline characteristics, including comorbidities, severity level of depression diagnosis (if a 
diagnosis existed at all), and measures of health care utilization, largely reflect the 
characteristics of the original SSRI cohort, which indicates a well-matched SNRI weighted 
cohort.
3.2 Risk of fractures
In our primary (as-treated, 60-day grace period, 360 days follow-up) analysis (Table 2), the 
rate of fractures was approximately equal in both the SSRI and SNRI cohorts (SNRI: 7.5 per 
1,000 person-years, 95% CI: 6.2–9.0; SSRI: 6.7 per 1,000 person-years, 95% CI: 6.3–7.1). 
Follow up through 5-years (1800 days) after initiation (Table 2) also showed that patients 
filling prescriptions for SNRIs showed a fracture rate of 6.9 per 1,000 person-years (95% 
CI: 5.9–8.2) while patients filling prescriptions for SSRIs showed a very similar fracture rate 
of 6.5 per 1,000 person-years (95% CI: 6.2–6.8). Over the first year after initiating therapy, 
those starting SNRIs, relative to those initiating with SSRIs, were not significantly more 
likely to suffer a fracture (hazard ratio = 1.11, 95% CI: 0.92–1.36) (Table 3). A similarly 
null finding was observed over the first five years after beginning therapy (hazard ratio = 
1.06, 95% CI: 0.90–1.26.) Additionally, for a cohort of patients with a depression diagnosis 
who initiated on either SNRIs or SSRIs, those initiating on SNRIs had a slightly elevated, 
though not statistically significantly elevated, rate of fracture (hazard ratio = 1.31, 95% CI: 
0.95–1.79) (Table 4). For a cohort of patients without a depression diagnosis who initiated 
on either SNRIs or SSRIs, those initiating on SNRIs had essentially the same rate of fracture 
as those initiating on SSRI (hazard ratio = 1.04, 95% CI: 0.80–1.34) (Table 4).
4. Discussion
Our study is the first of which we are aware to directly examine the differences in the risk of 
fracture associated with initiating SNRI compared to SSRI among subjects aged 50 years or 
older. In our study, there was no statistically significant differential in fracture risk between 
initiators of SNRIs vs. initiators of SSRIs during our follow-up period. Our finding that, on 
balance, SSRIs and SNRIs are correlated with similar fracture rates is consistent with the 
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notion that both SSRIs and SNRIs may contribute to fracture risk through different, though 
related pathways. It is possible, for example, that the extent to which serotonin-affecting 
drugs down regulate osteoblast activity and, in time, decrease bone mineral density[8, 3, 9, 
10], is similar to the effect of norepinephrine-affecting drugs, such as SNRIs [11, 12][18].
Although depression is known to be an independent risk factor for fracture, no prior work of 
which we are aware point to effect modification by depression status. Future work is needed 
to examine whether our secondary finding of a non-significant and modest increase in 
fracture risk among depressed patients initiating SNRIs, compared with those initiating 
SSRIs, can be replicated, or whether our finding in this regard is due to chance or residual 
confounding that is attenuated in our larger cohort of initiators both with and without 
depression.
There are several methodological issues to be considered regarding the current study. First, 
as depression itself has been shown to be a risk factor of osteoporosis [19–22], incomplete 
elimination of the impact of disease severity (or other potential confounders) during the 
matching process could affect our findings, especially in our cohort with depression 
diagnoses. Another limitation comes from our assessment of medication exposure. While we 
used the best-available data to define duration of exposure to the drug (longitudinal 
information on prescription refills) this may not accurately reflect the reality of drug-
adherence among SSRI and SNRI patients. It has been shown that non-adherence to 
antidepressants is a prevalent phenomenon [23, 24], but whether there are differences in 
adherence between SSRIs and SNRIs has not been reported in the previous literature to our 
knowledge. Nevertheless, our findings are similar for grace periods from 7 days to 60 days, 
suggesting that to the extent that antidepressant persistence is a reasonable proxy for 
antidepressant adherence, our findings may not be largely affected by differential adherence. 
Because there are many reasons people stop antidepressant therapy, including some side-
effects that would not be measured in administrative data but might be related to underlying 
fracture risk, we did not perform analyses on the effects of drug discontinuation as this 
would have opened up our findings to more unmeasured confounding. We do not have 
information on the magnitude of patients obtaining prescriptions outside of the PharMetrics 
claims database, but we have no reason to believe that SSRI initiators are any more likely or 
less likely to purchase medication out of plan than are SNRI initiators. Due to limitation in 
numbers of subjects and events, we did not have sufficient statistical power to report 
findings that are stratified under specific risk factors, for example, age of the subjects, or to 
parse fractures by type. Finally, we did not perform dose-response analyses as our study was 
not powered to do so; further, doses across drug classes (SNRI vs. SSRI) are not directly 
comparable.
Conclusions
Despite the stated limitations, our null findings with respect to fracture rates comparing 
SNRI and SSRI antidepressant initiators suggest that although mechanically plausible, 
SSRIs do not materially increase fracture risk any more than do SNRIs, the class of 
antidepressants next most likely to be prescribed today. Given the frequency with which 
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antidepressant medications are prescribed, more research is needed to fully understand the 
relative risks and benefits of prescribing these classes of antidepressants.
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• There is no statistically significant difference in rate of fracture among patients 
who initiate SNRIs versus those who initiate SSRIs.
• Future studies should examine whether the elevated fracture risk trend we 
observe among patients with depression who initiate on SNRIs is present among 
high fracture-risk populations.
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N=61,612 SNRI Weighted to SSRI
Age
 50–54 95,920 (28.6%) 20,786 (33.7%) 28.2%
 55–59 80,093 (23.9%) 16,779 (27.2%) 24.4%
 60–64 59,918 (17.9%) 11,313 (18.4%) 18.0%
 65–74 50,208 (15.0%) 7,810 (12.7%) 14.5%
 75–84 33,072 (9.9%) 3,739 (6.1%) 9.7%
 85–99 15,935 (4.8%) 1,185 (1.9%) 5.2%
Sex, M 119,950 (35.8%) 18,379 (29.8%) 36.3%
Attention deficit hyperactivity disorder (ADHD) 1,407 (0.4%) 422 (0.7%) 0.4%
Antipsychotics 14,004 (4.2%) 3,044 (4.9%) 4.4%
Anxiety 59,467 (17.7%) 7,897 (12.8%) 18.4%
Cardiac Arrhythmias 37,519 (11.2%) 5,239 (8.5%) 11.5%
Rheumatoid Arthritis 6,481 (1.9%) 1,786 (2.9%) 1.9%
Barbiturate 406 (0.1%) 62 (0.1%) 0.1%
Beta Blockers 71,810 (21.4%) 11,040 (17.9%) 21.6%
Benzodiazepine 82,224 (24.5%) 13,580 (22.0%) 25.0%
Bipolar Disorder 2,669 (0.8%) 816 (1.3%) 0.9%
History of Falls, Syncope or Gait Abnormality 41,229 (12.3%) 7,211 (11.7%) 12.6%
Suicidal Ideation 498 (0.1%) 106 (0.2%) 0.2%
Bone Mineral Density Scan 30,770 (9.2%) 6,956 (11.3%) 8.9%
Cataracts 36,208 (10.8%) 6,038 (9.8%) 10.8%
Myocardial Infarction 9,544 (2.8%) 1,199 (1.9%) 3.0%
Paraplegia and Hemiplegia 1,429 (0.4%) 315 (0.5%) 0.5%
Moderate or Severe Liver Disease 902 (0.3%) 129 (0.2%) 0.3%
AIDS/HIV 431 (0.1%) 88 (0.1%) 0.1%
Peripheral Vascular Disease 21,215 (6.3%) 3,772 (6.1%) 6.5%
Peptic Ulcer Disease 4,014 (1.2%) 688 (1.1%) 1.3%
Congestive Heart Failure 19,523 (5.8%) 2,531 (4.1%) 6.1%
Asthma/Chronic Obstructive Pulmonary Disease (COPD) 51,384 (15.3%) 8,866 (14.4%) 15.7%
Cox-2 Inhibitors 20,816 (6.2%) 4,768 (7.7%) 6.3%
Crohn Disease/Gastroenteritis 11,037 (3.3%) 2,096 (3.4%) 3.4%
Alzheimer or Other Dementia 15,570 (4.6%) 1,586 (2.6%) 5.0%
Diabetes 58,086 (17.3%) 11,721 (19.0%) 17.7%
Severity Level of Depression Diagnosis
 T1: Primary Inpatient Diagnosis <=30 Days Pre-Index Date 866 (0.3%) 180 (0.3%) 0.3%
 T2: Primary Inpatient Diagnosis 31–360 Days Pre-Index Date 254 (0.1%) 91 (0.1%) 0.1%


















N=61,612 SNRI Weighted to SSRI
 T3: Non-Primary Inpatient Diagnosis <=360 Days Pre-Index Date 5,968 (1.8%) 971 (1.6%) 1.9%
 T4: 2+ Outpatient Diagnosis <=360 Days Pre-Index Date 48,163 (14.4%) 8,869 (14.4%) 15.1%
 T5: 1 Outpatient Diagnosis <=360 Days Pre-Index Date 45,774 (13.7%) 5,902 (9.6%) 14.2%
 T6: No Diagnosis 234,121 (69.9%) 45,599 (74.0%) 68.4%
Glucocorticosteroids 47,435 (14.2%) 10,357 (16.8%) 14.2%
H-2 Antagonists 16,146 (4.8%) 2,306 (3.7%) 4.8%
Hip Fracture 2,253 (0.7%) 279 (0.5%) 0.7%
Humerus Fracture 1,360 (0.4%) 242 (0.4%) 0.4%
Hyperparathyroidism 1,313 (0.4%) 257 (0.4%) 0.4%
Hyperthyroidism 4,095 (1.2%) 783 (1.3%) 1.2%
Kyphosis 2,862 (0.9%) 786 (1.3%) 0.9%
Liver Disease 12,701 (3.8%) 2,405 (3.9%) 3.9%
Malignant Neoplasm 39,968 (11.9%) 8,485 (13.8%) 11.5%
Other nonsteroidal anti-inflammatory drug (NSAIDs) 62,762 (18.7%) 13,904 (22.6%) 18.7%
# of Prescription Drugs
 1 (antidepressant only) 16,279 (4.9%) 3,083 (5.0%) 4.9%
 2–3 49,631 (14.8%) 8,304 (13.5%) 14.7%
 4–5 55,563 (16.6%) 8,988 (14.6%) 16.5%
 6–9 94,994 (28.3%) 16,521 (26.8%) 28.3%
 10+ 118,679 (35.4%) 24,716 (40.1%) 35.7%
# of Hospitalizations, 1+ 60,258 (18.0%) 9,892 (16.1%) 18.3%
Number of Outpatient Visits
 <5 53,861 (16.1%) 8,823 (14.3%) 16.1%
 5–9 61,093 (18.2%) 9,572 (15.5%) 18.1%
 10–19 92,445 (27.6%) 15,845 (25.7%) 27.6%
 20–39 81,406 (24.3%) 16,196 (26.3%) 24.4%
 40+ 46,341 (13.8%) 11,176 (18.1%) 13.9%
Overweight or Obese 13,570 (4.0%) 3,007 (4.9%) 4.0%
Osteoporosis 20,431 (6.1%) 3,828 (6.2%) 6.0%
Other Fracture 12,291 (3.7%) 2,345 (3.8%) 3.8%
Antiparkinson Drug 7,281 (2.2%) 1,643 (2.7%) 2.2%
Personality Disorder 968 (0.3%) 211 (0.3%) 0.3%
PPI 54,090 (23.1%) 10,896 (23.9%) 23.6%
Radius/Ulna Fracture 1,889 (0.6%) 351 (0.6%) 0.6%
Renal Disease 4,728 (1.4%) 664 (1.1%) 1.4%
Schizophrenic Disorder 908 (0.3%) 150 (0.2%) 0.3%
Ischemic Stroke 12,595 (3.8%) 1,631 (2.6%) 4.1%
Suicide Attempt 184 (0.1%) 34 (0.1%) 0.1%
Thiazides 31,528 (9.4%) 5,271 (8.6%) 9.3%


















N=61,612 SNRI Weighted to SSRI
Thyroid 43,939 (13.1%) 8,504 (13.8%) 13.1%
Urinary Incontinence 7,974 (2.4%) 1,553 (2.5%) 2.4%
Vertebral Fracture 3,328 (1.0%) 648 (1.1%) 1.1%
SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin norepinephrine reuptake inhibitor
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Table 3
SNRI vs. SSRI Fracture Hazard Ratios
Analysis 1-Year HR (95% CI) 5-Year HR (95% CI)
7-Day GP 1.01 (0.78, 1.30) 1.03 (0.82, 1.30)
14-Day GP 0.98 (0.78, 1.25) 1.01 (0.82, 1.24)
30-Day GP 1.02 (0.83, 1.26) 1.02 (0.85, 1.23)
60-Day GP 1.11 (0.92, 1.36) 1.06 (0.90, 1.26)
90-Day GP 1.12 (0.93, 1.36) 1.06 (0.90, 1.26)
180-Day GP 1.09 (0.90, 1.31) 1.04 (0.88, 1.22)
360-Day GP 1.03 (0.86, 1.24) 1.01 (0.87, 1.18)
First treatment carried forward 1.02 (0.87, 1.21) 0.98 (0.87, 1.10)
SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin norepinephrine reuptake inhibitor GP = grace period; HR = hazard ratio; CI = 
confidence interval
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Table 4
SNRI vs. SSRI Fracture Hazard Ratios, with vs. without depression diagnoses
With Depression, Excluding Bipolar and Schizophrenic 
Disorders
Without Depression
Analysis 1-Year HR (95% CI) 5-Year HR (95% CI) 1-Year HR (95% CI) 5-Year HR (95% CI)
7-Day GP 1.34 (0.91, 1.96) 1.35 (0.95, 1.92) 0.83 (0.59, 1.17) 0.84 (0.62, 1.15)
14-Day GP 1.27 (0.88, 1.84) 1.26 (0.90, 1.76) 0.84 (0.62, 1.15) 0.87 (0.66, 1.13)
30-Day GP 1.22 (0.86, 1.72) 1.19 (0.88, 1.62) 0.92 (0.70, 1.21) 0.91 (0.72, 1.15)
60-Day GP 1.31 (0.95, 1.79) 1.22 (0.92, 1.60) 1.04 (0.80, 1.34) 0.98 (0.78, 1.22)
90-Day GP 1.30 (0.95, 1.77) 1.21 (0.92, 1.58) 1.05 (0.82, 1.34) 0.98 (0.79, 1.22)
180-Day GP 1.23 (0.91, 1.66) 1.15 (0.88, 1.50) 1.03 (0.81, 1.30) 0.97 (0.79, 1.19)
360-Day GP 1.17 (0.87, 1.57) 1.12 (0.87, 1.45) 0.98 (0.78, 1.23) 0.95 (0.78, 1.15)
First treatment 
carried forward
1.12 (0.86, 1.46) 1.06 (0.88, 1.29) 1.01 (0.82, 1.25) 0.94 (0.81, 1.09)
SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin norepinephrine reuptake inhibitor GP = grace period; HR = hazard ratio; CI = 
confidence interval
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